炎症性肠病合并血液系统肿瘤  

Inflammatory Bowel Disease Coexisted with Hematologic Malignancy

作　　者：王智峰[1] 周艳华[1] 刘玉兰[1] 

机构地区：[1]北京大学人民医院消化内科

出　　处：《胃肠病学》2010年第10期583-586,共4页Chinese Journal of Gastroenterology

摘　　要：炎症性肠病（IBD）合并血液系统肿瘤临床上较罕见.近年IBD患者中血液系统肿瘤的发病风险是否增加已受到越来越多的关注.多数研究认为免疫抑制剂尤其是嘌呤类似物可增加IBD患者淋巴瘤的发病风险,而IBD中白血病和骨髓增生异常综合征（MDS）的发病风险是否增加仍需进一步研究.IBD合并血液系统肿瘤的发病机制尚不明确,造血干细胞移植可能是其最佳的治疗选择.Inflammatory bowel disease （IBD） coexisted with hematologic malignancy is rare in clinical practice. Recently, the risk of hematologic malignancy in patients with IBD has been a growing concern. An increased risk for lymphoma in IBD patients treated with immunosuppressants especially purine analogues has been demonstrated in many studies. The risk of leukemia and myelodysplastic syndrome （MDS） in IBD patients needs further study. The pathogenesis of IBD coexisted with hematologic malignancy remains unclear. Hematopoietic stem cell transplantation might be the best option of treatment.

关 键 词：炎症性肠病 淋巴瘤 白血病 骨髓增生异常综合征 诊断 造血干细胞移植 

分 类 号：R574[医药卫生—消化系统] R733[医药卫生—内科学]